AMPIO to pay out $12.8 million in next eleven months- by Dec 2013 for two drug tests
This is from latest filing- that is why the drop.
On January 21, 2013, Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) entered into a Master Service Agreement and Scope of Work (the “Ampion Agreement”) with a clinical research organization (the “Ampion CRO”). Pursuant to the Ampion Agreement, the Ampion CRO will provide study management services in connection with the Company’s clinical trial of Ampion TM for the treatment of osteoarthritis of the knee. The consideration payable by Ampio to the Ampion CRO in connection with these services totals approximately $6.8 million, which is expected to be paid over the course of the next eleven months, subject to the achievement by the Ampion CRO of specified milestones. The Ampion Agreement is effective as of January 21, 2013 and continues until the Ampion Agreement is terminated in accordance with its terms. Either party may terminate the Ampion Agreement with or without cause upon 30 days written notice.
On January 21, 2013, Ampio entered into a Master Services Agreement and Scope of Work (the “Optina Agreement”) with a clinical research organization (the “Optina CRO”). Pursuant to the Optina Agreement, the Optina CRO will provide clinical trial services in connection with the Company’s clinical trial of Optina TM for the treatment of diabetic macular edema. The consideration payable by Ampio to the Optina CRO in connection with these services totals approximately $6.0 million which is expected to be paid over the course of the next eleven months, based on specified milestones. The Optina Agreement is effective as of January 21, 2013 and continues until completion of the services, unless earlier terminated in accordance with the Optina Agreement.
The biggest item relative to Zertane is the patent portfolio covering the combination of ED and PE. Certainly PE is big, and the fact that the FDA is even entertaining a drug for what they had previously refused to consider a medical condition is huge. However, as Viagra, Cialis et. al. come off patent, big pharma needs the next big thing is this field. To be able to go after the PE market in the US is a big incentive for them, but to be able to combine it with ED, thus extending the branded life of their products is enormous.
Yes... AMPE will most likely not internally develop and market Zertane. The opportunity and benefit to big pharma is too great.
I don't expect too much up front, but there should be some huge milestone payments down the road and/or a significant prospect of an ongoing revenue stream.
Zertane appears to be somewhat of outlier in AMPE's portfolio. Expect it to be gone within a short period time, but providing some funding and revenue streams to support their other (even greater) revenue opportunities.